BMS will obtain exclusive rights for the development and marketing of obexelimab in licensed regions. Credit: Stock-Asso / Shutterstock.com.

Zenas BioPharma and Bristol Myers Squibb (BMS) have signed a licence and partnership agreement for the development and commercialisation of the antibody obexelimab to treat autoimmune ailments.

The geographies comprised in the agreement include Australia, Hong Kong, Japan, Singapore, South Korea and Taiwan.  

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

As per the deal terms, BMS will obtain exclusive rights for the development and marketing of the antibody in these licensed regions.

BMS will make an upfront cash payment of $50m to Zenas in this regard.

Zenas is also entitled to receive milestone payments on meeting specific development, regulatory and commercial goals, in addition to royalty payments on net obexelimab sales in the licensed territories.

BMS will also make an equity investment in Zenas in association with the new deal. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

An investigational bifunctional, non-cytolytic, humanised monoclonal antibody, obexelimab is being analysed as a subcutaneous injection in a Phase III clinical trial for IgG4-related disease. 

It is also being evaluated in a Phase II/III trial for warm antibody auto-immune hemolytic anaemia.

The partnership is part of Zenas’ strategy to deliver immunology-based therapies to patients globally by utilising BMS’s capabilities in immune-mediated ailments.

Zenas BioPharma founder and CEO Lonnie Moulder said: “This collaboration marks an important step forward in realising our vision for obexelimab to benefit patients living with autoimmune diseases globally.

“The deeply experienced and passionate team at Bristol Myers Squibb is an ideal partner based on their proven development, regulatory and commercial capabilities in Japan and throughout the licensed territory.”

In June 2023, BMS received approval from the European Commission for Opdivo (nivolumab) plus platinum-based chemotherapy for resectable non-small cell lung cancer.